Erasca, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of precision oncology therapies. Founded in 2018 and headquartered in San Diego, California, the company's mission is to "erase cancer" by comprehensively shutting down the RAS/MAPK signaling pathway, one of the most frequently mutated pathways in human cancers. Erasca employs a modality-agnostic approach, utilizing both small molecule inhibitors and molecular glues to target critical upstream and downstream signaling nodes, target RAS directly, and block escape routes that emerge in response to treatment.
As a pre-revenue, clinical-stage company, Erasca does not yet generate commercial product revenue and relies on capital markets and strategic partnerships to fund its operations. Its lead product candidates include ERAS-0015, a pan-RAS molecular glue currently in Phase 1 clinical trials for the treatment of RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor. The company has established strategic collaborations to advance its pipeline, including a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA (pembrolizumab). Erasca operates primarily in the United States but has expanded its clinical and licensing footprint globally, including securing worldwide rights to ERAS-0015 through an expanded agreement covering China, Hong Kong, and Macau. The company's competitive position is anchored by its deep, specialized focus on the RAS/MAPK pathway and its potentially best-in-class pan-RAS molecular glue technology.
